Welcome to our dedicated page for LifeStance Health Group SEC filings (Ticker: LFST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LifeStance Health Group filings document the company's outpatient mental healthcare business, Nasdaq-listed common stock and public-company governance. Its 8-K reports furnish quarterly and annual results, Regulation FD presentations, operating metrics, cash flow commentary and capital allocation disclosures.
The filing record also covers proxy matters, director elections, executive compensation, officer and board changes, equity incentive awards, share repurchase authorization, and common stock offering documents under shelf registration statements. These disclosures describe governance structure, securities registration, material agreements, stockholder selling activity, repurchases, and the risks and reporting obligations associated with LifeStance's virtual and in-person outpatient care model.
LifeStance Health Group, Inc. (LFST) reported that entities associated with TPG GP A, LLC, James G. Coulter, and Jon Winkelried indirectly sold 18,409,705 shares of common stock on September 11, 2026 at $12.29 per share in an open-market or private transaction. After this sale, TPG VIII Lynnwood Holdings Aggregation, L.P., the TPG-affiliated entity referenced in the footnotes, directly held 79,691,702 shares of LifeStance common stock. The reporting persons state that they may be deemed to beneficially own these securities only to the extent of their respective pecuniary interests and expressly disclaim beneficial ownership beyond that. No Rule 10b5-1 trading plan is reported for this transaction.
LifeStance Health Group, Inc. (LFST) announced that it entered into an Underwriting Agreement with Barclays Capital Inc. and certain selling stockholders for an underwritten secondary offering of 22,250,000 shares of its common stock under an existing Form S-3 registration statement.
All offered shares were sold by the selling stockholders, and the company received no proceeds from the offering. Under the same agreement, LifeStance agreed to purchase 2,000,000 of those shares from the underwriter at the same price the underwriter paid the selling stockholders. The underwriter did not receive compensation for the shares repurchased by the company. The offering closed on September 11, 2026.
LifeStance Health Group, Inc. (LFST) has filed a prospectus supplement for a secondary offering of 22,250,000 shares of common stock by existing selling stockholders. LifeStance is not issuing new shares and will not receive any proceeds from the stockholders’ sales.
Contingent on the closing of this offering, LifeStance intends to repurchase 2,000,000 of the offered shares from the underwriter for approximately $24.58 million, funded with cash on hand under its existing share repurchase program. The shares purchased in the repurchase will be retired and will no longer be outstanding. LFST common stock trades on Nasdaq under the symbol LFST.
LifeStance Health Group, Inc. (LFST) has filed a preliminary prospectus supplement for a secondary offering of 22,250,000 shares of common stock, all to be sold by existing selling stockholders. LifeStance is not issuing new shares and will not receive proceeds from these sales; the selling stockholders will receive the offering proceeds.
Conditioned on the completion of the offering, LifeStance intends to repurchase 2,000,000 shares from the underwriter using cash on hand under its existing share repurchase program and then retire those shares, which will no longer be outstanding. This repurchase is contingent on the offering’s closing, while the offering itself is not conditioned on the repurchase. Shares outstanding were 382,154,147 as of September 1, 2026, and LFST last traded at $12.80 on September 8, 2026.
LifeStance Health Group, Inc. (LFST) reported that Chief Executive Officer and director David Bourdon transferred 150,000 shares of common stock on September 2, 2026 in an "other acquisition or disposition" transaction. According to the disclosure, the shares were transferred to a family member for no value for estate planning purposes, and Bourdon now holds 1,248,247 shares directly.
LifeStance Health Group, Inc. (LFST) reported that Chief Technology Officer Vukasin Paunovich sold 42,067 shares of common stock on September 2, 2026 in a sale characterized as an open market or private transaction at a weighted average price of $12.87 per share, with individual trades ranging from $12.86 to $12.905. After this transaction, he directly owned 205,379 shares of LifeStance common stock.
LifeStance Health Group, Inc. (LFST) is the issuer of common stock for which Vaughn (Vukasin) Paunovich has filed a Rule 144 notice to sell shares held at Fidelity Brokerage Services LLC. The notice covers 42,067 shares of common stock that vested as restricted stock on June 11, 2026, received from the issuer as compensation. The filing also reports that Paunovich sold 44,394 shares of LFST common stock in the prior three months on August 10, 2026.
LifeStance Health Group, Inc. (LFST) reported that Chief People Officer Ann Varanakis had 8,156 shares of common stock withheld on August 24, 2026 to satisfy tax withholding obligations upon vesting of restricted stock units. The shares were valued at $12.16 per share and were not sold in the open market, leaving her with 413,881 shares held directly after the transaction.
LifeStance Health Group, Inc. (LFST) director Teresa DeLuca reported selling 7,500 shares of common stock on 2026-08-14 at a weighted average price of $12.68 per share, in multiple trades between $12.68 and $12.695. According to the disclosure, this was a required “sell to cover” transaction to satisfy tax withholding obligations arising from the vesting of restricted stock units and does not represent a discretionary trade. Following this sale, DeLuca directly holds 97,093 shares of LifeStance common stock.
LifeStance Health Group, Inc. director Teresa DeLuca reported a sale of common stock. On 2026-08-13, she sold 20,441 shares of common stock at a reported price of $12.23 per share in a sale characterized as an open market or private transaction. Following this transaction, she directly holds 104,593 shares of LifeStance Health Group common stock.